Immix Biopharma has released a statement in response to the recent notification from the FDA regarding changes in labeling for approved CAR-T products. Dr. Ilya Rachman, the CEO of Immix Biopharma, expressed strong confidence in the potential of their CAR-T candidates, particularly NXC-201, to address the pressing medical needs of patients with relapsed/refractory AL Amyloidosis. The statement emphasized the favorable tolerability profile of NXC-201 and highlighted the absence of observed secondary T-cell malignancies in the ongoing clinical trial.
Gabriel Morris, the Chief Financial Officer of Immix Biopharma, also emphasized the unique suitability of NXC-201 in the treatment of AL Amyloidosis and other autoimmune indications. This assertion was based on the interim clinical data gathered from 73 patients to date.
NXC-201, the company’s leading cell therapy asset, has demonstrated promising results in the treatment of relapsed/refractory AL Amyloidosis. The interim clinical data revealed impressive overall response rates of 100% and 95% in these patient populations. Notably, NXC-201 has been granted Orphan Drug Designation (ODD) by the FDA for both AL Amyloidosis and multiple myeloma. The favorable tolerability profile of NXC-201 has also paved the way for its potential use in treating autoimmune indications such as systemic lupus erythematosus, myasthenia gravis, and multiple sclerosis.
AL Amyloidosis affects approximately 15,000 patients globally each year, and the market for Amyloidosis was valued at $3.6 billion in 2017, with an expected increase to $6 billion by 2025. Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company dedicated to pioneering personalized therapies for oncology.
The ongoing Phase 1b/2a clinical trial for NXC-201, known as NEXICART-1 (NCT04720313), has yielded promising results, prompting the company to plan further studies of NXC-201 in relapsed/refractory AL Amyloidosis at U.S. sites following IND clearance. NXC-201 has the potential to become the world’s first “Single-Day CRS” CAR-T therapy, allowing patients to return home faster.
To learn more about Immix Biopharma and their groundbreaking work, please visit their official website or refer to reputable sources such as Biospace, Nasdaq, Street Insider, and Clinical Trials Arena.
IMMX Stock Shows Promising Signs with Positive Performance on January 24, 2024
On January 24, 2024, IMMX stock exhibited positive performance, showing promising signs for investors. IMMX was observed to be trading in the middle of its 52-week range, indicating stability in its price movement. Furthermore, IMMX was trading above its 200-day simple moving average, indicating positive sentiment among investors. The price of IMMX shares experienced a notable increase of $0.26 since the market last closed, representing a rise of 5.62% in the stock’s value. IMMX stock opened at $4.61 on January 24, 2024, $0.09 lower than its previous close. Overall, the performance of IMMX stock on January 24, 2024, showcased positive momentum.
IMMX Stock Performance on January 24, 2024: Mixed Results and Considerations for Investment Decisions
On January 24, 2024, IMMX stock experienced a mixed performance. IMMX reported a net income of -$8.23 million for the past year, indicating a significant loss. However, the net income increased by 66.25% compared to the previous year. In the third quarter, IMMX’s net income stood at -$4.28 million, showing a decrease of 19.7% compared to the previous quarter. The net income has still increased by 66.25% since the same period last year. IMMX reported an EPS of -$0.62 for the past year, indicating a loss per share. However, the EPS has increased by 66.25% since the previous year. In the third quarter of 2023, IMMX’s EPS was -$0.23, representing a 3.11% increase compared to the previous quarter. The lack of total revenue data makes it challenging to form a comprehensive analysis of IMMX’s stock performance. It is essential to consider other factors, such as industry trends, market conditions, and company-specific developments, before making any investment decisions. Overall, the performance of IMMX stock on January 24, 2024, suggests a mixed bag of results.
